AbbVie's experimental hep c combo proves highly effective across genotypes

The combination treatment would also offer improved convenience as a once-daily regimen, compared to the company's multipill Viekira Pak. 

By Nicole Gray • April 18, 2016

EASL 2016: Merck's 'no patient left behind' approach to hepatitis C

The company's hep c med Zepatier faces an uphill battle as it competes against Gilead's dominant treatments, leading Merck to look at typically untreated patient populations. 

By Nicole Gray • April 18, 2016

Explore the Trendline➔

Oncology's research boom

More than one quarter of the medcines cleared by the FDA's main review office since 2015 have been cancer drugs, a tally that reflects the advent of cancer immunotherapy as well as continued progress in matching treatment to genetics.

By BioPharma Dive staff

Bristol-Myers' Opdivo gets boost from long-term survival data

More than a third of patients with advanced melanoma who received Opdivo survived past five years. 

By Ned Pagliarulo • April 18, 2016

Review of NCI facilities halts patient enrollment in Kite T-cell studies

Separately, the biotech announced three patients in an early stage trial of one of its T-cell treatments had continued to show durable responses against solid tumors. 

By Ned Pagliarulo • April 17, 2016

Most cancer drug labels don't include patient experiences: study

As a comparison, researchers found nearly 25% of other drugs included patient-reported outcomes information. 

By Nicole Gray • April 15, 2016

After Alzheimer's drug passes safety review, AstraZeneca and Lilly push into Phase 3

Despite the many drug development failures in the Alzheimer's space, several companies are hopeful so-called BACE inhibitors can slow progression of the disease. 

By Ned Pagliarulo • April 8, 2016

In phase 3 collaboration, Merck and Pfizer testing PDL1/TKI combo

The trial aims to test the efficacy of the combo against renal cell carcinoma, compared to Pfizer's older drug Sutent. 

By Ned Pagliarulo • April 5, 2016

ACC 2016: Boehringer's Pradaxa 'antidote' passes real-world test

Praxbind, a reversal agent for the blood thinner Pradaxa, has been a key feature in Boehringer's new marketing campaign. 

By Nicole Gray • April 4, 2016

Study shows no clinical benefit from Lilly's failed cholesterol drug

Lilly had previously discontinued a 12,000 person trial for the once-heralded CETP inhibitor evacetrapib due to lack of efficacy.

By Ned Pagliarulo • April 4, 2016

GSK gene therapy for rare immune disorder wins EMA approval

Children born with the disorder have almost no ability to fight off everyday infections due to a compromised immune system. 

By Ned Pagliarulo • April 3, 2016

ACC 2016: Novartis' Entresto reduces risk of hospitalization in HF patients

The data will likely help Novartis as it builds out recent pay-for-performance deals with Aetna and Cigna, two major insurers. 

By Nicole Gray • April 3, 2016

Lilly's arthritis drug baricitinib notches another success

The drug will have significant competition however, as a number of companies are also lining up new rheumatoid arthritis treatments. 

By Nicole Gray • April 1, 2016

FDA panel says benefits outweigh risks for Acadia's Parkinson's drug

The advisory committee voted 12-2 in favor of the Parkinson's disease psychosis drug, setting the stage for a FDA decision May 1. 

By Ned Pagliarulo • March 29, 2016

Theranos blood testing inconsistent with other labs, study shows

Compared to testing by LabCorp and Quest Diagnostics, Theranos' technology was 1.6 times more likely to yield abnormal results.

By Nicole Gray • March 29, 2016

New phase 2 data boosts prospects for Alder's migraine drug

The company hopes to stay abreast of competing companies, such as Amgen and Lilly, which are developing drugs using the same mechanism as Alder's ALD403. 

By Ned Pagliarulo • March 28, 2016

New poll finds widespread support for cancer research funding

According to the STAT-Harvard poll, over 80% of Americans believe a 20% increase in federal research funding would be appropriate or not enough. 

By Nicole Gray • March 28, 2016

Amid safety concerns, FDA adcomm set to review Acadia's Parkinson's drug

Acadia's Nuplazid is forecast for over $1 billion in 2020 sales, but has to clear regulatory hurdles in Tuesday's advisory committee review. 

By Nicole Gray • March 28, 2016

In major stroke study, AstraZeneca's Brilinta fails to beat aspirin

The global trial measured the reduction in recurrent events after a patient first suffers a stroke. 

By Ned Pagliarulo • March 23, 2016

BioMarin's PKU drug meets primary goal in phase 3, but falls short on secondary endpoints

The company hopes to file for approval with the FDA by the end of the year. 

By Nicole Gray • March 22, 2016

Biden names corporate exec Greg Simon to lead Cancer Moonshot

Simon has previously worked with the charity FasterCures, as well as at Pfizer and as CEO of the life sciences finance company Poliwogg. 

By Nicole Gray • March 21, 2016

Johnson & Johnson's psoriasis drug Stelara succeeds in Phase 3

The blockbuster treatment proved effective against a placebo in treating Crohn's disease. 

By Ned Pagliarulo • March 18, 2016

In new deal, Kite Pharma partnering with Roche on cancer immunotherapy

The collaboration will explore combining Kite's leading CAR-T therapy with Roche's atezolizumab. 

By Ned Pagliarulo • March 18, 2016

Top Gilead cancer researcher has left company

The news of the departure comes as Gilead has halted six trials for its cancer drug Zydelig after an increased number of adverse events.

By Nicole Gray • March 18, 2016

In limited study, NIH-developed dengue vaccine proves 100% effective

Researchers hope their work can help inform development of a vaccine for Zika virus, which shares similarities with dengue. 

By Nicole Gray • March 17, 2016

EMA finalizes clinical trial redaction guidelines

Pharmaceutical companies claim publication of all clinical trial data would compromise trade secrets. Advocates for transparency, on the other hand, argue more information is need to enhance the ability to replicate important findings. 

By Nicole Gray • March 16, 2016